4.5 Article

An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides

Journal

Biomicrofluidics
Volume 9, Issue 5, Pages -

Publisher

AMER INST PHYSICS
DOI: 10.1063/1.4931394

Keywords

-

Funding

  1. European grants [LSHB CT 06 037953, FP7-NMP-09-246513]

Ask authors/readers for more resources

We present an integrated microfluidic chip for detection of beta-amyloid (A beta) peptides. A beta peptides are major biomarkers for the diagnosis of Alzheimer's disease (AD) in its early stages. This microfluidic device consists of three main parts: (1) An immunocapture microcolumn based on self-assembled magnetic beads coated with antibodies specific to A beta peptides, (2) a nano-porous membrane made of photopolymerized hydrogel for preconcentration, and (3) a microchip electrophoresis (MCE) channel with fluorescent detection. Sub-milliliter sample volume is either mixed off-chip with antibody coated magnetic beads and injected into the device or is injected into an already self-assembled column of magnetic beads in the microchannel. The captured peptides on the beads are then electrokinetically eluted and re-concentrated onto the nano-membrane in a few nano-liters. By integrating the nano-membrane, total assay time was reduced and also off-chip re-concentration or buffer exchange steps were not needed. Finally, the concentrated peptides in the chip are separated by electrophoresis in a polymer-based matrix. The device was applied to the capture and MCE analysis of differently truncated peptides A beta (1-37, 1-39, 1-40, and 1-42) and was able to detect as low as 25 ng of synthetic A beta peptides spiked in undiluted cerebrospinal fluid (CSF). The device was also tested with CSF samples from healthy donors. CSF samples were fluorescently labelled and pre-mixed with the magnetic beads and injected into the device. The results indicated that A beta 1-40, an important biomarker for distinguishing patients with frontotemporal lobe dementia from controls and AD patients, was detectable. Although the sensitivity of this device is not yet enough to detect all A beta subtypes in CSF, this is the first report on an integrated or semi-integrated device for capturing and analyzing of differently truncated Ab peptides. The method is less demanding and faster than the conventional Western blotting method currently used for research. (C) 2015 AIP Publishing LLC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales

Kiran Samra, Amy M. MacDougall, Georgia Peakman, Arabella Bouzigues, Martina Bocchetta, David M. Cash, Caroline Greaves, Rhian S. Convery, John C. van Swieten, Lize Jiskoot, Harro Seelaar, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonca, Chris R. Butler, Alexander Gerhard, Simon Ducharme, Isabelle Le Ber, Pietro Tiraboschi, Isabel Santana, Florence Pasquier, Johannes Levin, Markus Otto, Sandro Sorbi, Jonathan D. Rohrer, Lucy L. Russell

Summary: This study investigated the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD). The results showed that motor symptoms are present in mutation carriers at all disease stages, and including motor symptoms in a rating scale can provide a more accurate assessment of disease severity and incorporate a wider spectrum of FTD phenotypes in the same clinical trial.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales

Kiran Samra, Amy Macdougall, Georgia Peakman, Arabella Bouzigues, Martina Bocchetta, David M. Cash, Caroline Greaves, Rhian S. Convery, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonca, Christopher R. Butler, Alexander Gerhard, Simon Ducharme, Isabelle Le Ber, Pietro Tiraboschi, Isabel Santana, Florence Pasquier, Johannes Levin, Markus Otto, Sandro Sorbi, Jonathan D. Rohrer, Lucy L. Russell

Summary: A study on frontotemporal dementia found that neuropsychiatric symptoms occur in mutation carriers at all disease stages, with hallucinations and delusions providing additional staging benefit. The inclusion of these features in rating scales could improve the evaluation of disease progression.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries

Giancarlo Logroscino, Marco Piccininni, Caroline Graff, Orla Hardiman, Albert C. Ludolph, Fermin Moreno, Markus Otto, Anne M. Remes, James B. Rowe, Harro Seelaar, Eino Solje, Elka Stefanova, Latchezar Traykov, Vesna Jelic, Melissa Taheri Rydell, Niall Pender, Sarah Anderl-Straub, Myriam Barandiaran, Alazne Gabilondo, Johanna Kruger, Alexander G. Murley, Timothy Rittman, Emma L. van der Ende, John C. van Swieten, Paeivi Hartikainen, Gorana Mandic Stojmenovic, Shima Mehrabian, Luisa Benussi, Antonella Alberici, Maria Teresa Dell'Abate, Chiara Zecca, Barbara Borroni

Summary: This study examined the incidence of frontotemporal lobar degeneration (FTLD)-associated syndromes in Europe and found that they are more common than previously recognized, warranting diagnosis at any age. The findings have important implications for health and social care planning, as well as the design of future clinical trials.

JAMA NEUROLOGY (2023)

Article Neuroimaging

Multiclass prediction of different dementia syndromes based on multi-centric volumetric MRI imaging

Leonie Lampe, Hans-Jurgen Huppertz, Sarah Anderl-Straub, Franziska Albrecht, Tommaso Ballarini, Sandrine Bisenius, Karsten Mueller, Sebastian Niehaus, Klaus Fassbender, Klaus Fliessbach, Holger Jahn, Johannes Kornhuber, Martin Lauer, Johannes Prudlo, Anja Schneider, Matthis Synofzik, Jan Kassubek, Adrian Danek, Arno Villringer, Janine Diehl-Schmid, Markus Otto, Matthias L. Schroeter

Summary: The study aimed to build a classifier for multiple dementia syndromes using MRI, and the results showed that the binary classification models achieved high prediction accuracies between 71% and 95%, with disease-specific atrophy patterns reflected in feature importance. The multi-syndrome model reached accuracies more than three times higher than chance level but was still far from 100%, and the performance varied across different dementia syndromes.

NEUROIMAGE-CLINICAL (2023)

Article Clinical Neurology

Blood β-synuclein is related to amyloid PET positivity in memory clinic patients

Patrick Oeckl, Marina Bluma, Marco Bucci, Steffen Halbgebauer, Konstantinos Chiotis, Anna Sandebring-Matton, Nicholas J. Ashton, Guglielmo Di Molfetta, Lana Grotschel, Miia Kivipelto, Kaj Blennow, Henrik Zetterberg, Irina Savitcheva, Agneta Nordberg, Markus Otto

Summary: Plasma beta-synuclein levels were found to be higher in individuals with Alzheimer's disease and mild cognitive impairment with amyloid-beta positivity. It demonstrated good discrimination and prediction of amyloid-beta status. The correlation between plasma beta-synuclein and amyloid-beta PET was observed in multiple cortical regions. These findings suggest that beta-synuclein is not a direct marker of amyloid-beta pathology and highlight the different longitudinal dynamics of synaptic degeneration and amyloid deposition in Alzheimer's disease.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease

Patrick Oeckl, Shorena Janelidze, Steffen Halbgebauer, Erik Stomrud, Sebastian Palmqvist, Markus Otto, Oskar Hansson

Summary: Beta-synuclein can serve as a synaptic blood biomarker for Alzheimer's disease, even in the preclinical stages. Higher levels of plasma beta-synuclein are observed in preclinical AD, mild cognitive impairment, and AD dementia. The levels are associated with amyloid and tau pathology, as well as cognitive impairment and temporal cortical thinning.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Cognitive Performance

Babak Hooshmand, Franziska Appold, Patrick Fissler, Robert Perneczky, Markus Otto, Hayrettin Tumani, Miia Kivipelto, Christine A. F. von Arnim

Summary: This study investigated the association between vitamin B12 status and biomarkers of Alzheimer's disease. The results suggest that vitamin B12-related markers are associated with AD biomarkers and cognitive performance. Vitamin B12 supplementation may be important in slowing down brain changes and cognitive decline.

ANNALS OF NEUROLOGY (2023)

Article Neurosciences

Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia

Aurelie P. Bussy, Jake P. Levy, Tristin Best, Raihaan Patel, Lani Cupo, Tim Van Langenhove, Jorgen E. Nielsen, Yolande Pijnenburg, Maria Landqvist M. Waldo, Anne M. L. Remes, Matthias L. Schroeter, Isabel Santana, Florence Pasquier, Markus Otto, Adrian Danek, Johannes Levin, Isabelle Le Ber, Rik Vandenberghe, Matthis Synofzik, Fermin Moreno, Alexandre de Mendonca, Raquel Sanchez-Valle, Robert Laforce, Tobias Langheinrich, Alexander Gerhard, Caroline R. Graff, Chris R. Butler, Sandro Sorbi, Lize Jiskoot, Harro C. Seelaar, John C. van Swieten, Elizabeth Finger, Maria Carmela Tartaglia, Mario Masellis, Pietro Tiraboschi, Daniela Galimberti, Barbara B. Borroni, James B. Rowe, Martina D. Bocchetta, Jonathan D. A. Rohrer, Gabriel A. Devenyi, M. Mallar Chakravarty, Simon Ducharme

Summary: Recent studies have shown that early cerebellar and subcortical changes are seen in the progression of genetic frontotemporal dementia due to specific gene mutations. This study aimed to investigate the relationship between cerebellar and subcortical atrophy and neuropsychiatric symptoms across different genetic mutations in FTD.

HUMAN BRAIN MAPPING (2023)

Article Clinical Neurology

The Behavioural Dysfunction Questionnaire discriminates behavioural variant frontotemporal dementia from Alzheimer's disease dementia and major depressive disorder

Anna Semenkova, Olivier Piguet, Andreas Johnen, Matthias L. Schroeter, Jannis Godulla, Christoph Linnemann, Markus Muhlhauser, Thomas Sauer, Markus Baumgartner, Sarah Anderl-Straub, Markus Otto, Ansgar Felbecker, Reto W. Kressig, Manfred Berres, Marc Sollberger

Summary: Based on the revised diagnostic criteria, the Behavioural Dysfunction Questionnaire (BDQ) was developed to discriminate between behavioural variant frontotemporal dementia (bvFTD) and non-bvFTD patients. BDQ-scores without any time criterion were found highly discriminatory between early-stage bvFTD and non-bvFTD groups, suggesting its potential for improving early diagnosis of bvFTD.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis

Ahmed Abdelhak, Lorenzo Barba, Michele Romoli, Pascal Benkert, Francesco Conversi, Lucio D'Anna, Ruturaj R. Masvekar, Bibiana Bielekova, Mercedes Prudencio, Leonard Petrucelli, James F. Meschia, Young Erben, Roberto Furlan, Rebecca De Lorenzo, Alessandra Mandelli, Raoul Sutter, Lisa Hert, Varenka Epple, Damiano Marastoni, Johann Sellner, Petra Steinacker, Anne Hege Aamodt, Lars Heggelund, Anne Margarita Dyrhol-Riise, Johan Virhammar, David Fallmar, Elham Rostami, Eva Kumlien, Kaj Blennow, Henrik Zetterberg, Hayrettin Tumani, Simona Sacco, Ari J. Green, Markus Otto, Jens Kuhle, Raffaele Ornello, Matteo Foschi, Samir Abu-Rumeileh

Summary: This study investigated the prognostic value of blood neurofilament light chain protein (NfL) levels in the acute phase of COVID-19. The results showed that elevated NfL levels were significantly associated with disease duration and severity, and higher NfL levels were linked to a higher likelihood of ICU admission, need of mechanical ventilation, and death. Therefore, blood NfL levels may have potential in predicting the prognosis of COVID-19.

JOURNAL OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Development of an ultrasensitive microfluidic assay for the analysis of Glial fibrillary acidic protein (GFAP) in blood

Badrieh Fazeli, Andre Huss, Nerea Gomez de San Jose, Markus Otto, Hayrettin Tumani, Steffen Halbgebauer

Summary: This study developed a sensitive and easy-to-use microfluidic assay to measure GFAP in blood, and confirmed previous findings of elevated GFAP levels in AD by applying the assay in a cohort of clinically characterized patients.

FRONTIERS IN MOLECULAR BIOSCIENCES (2023)

Article Clinical Neurology

Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort

Martina Bocchetta, Emily G. Todd, Arabella Bouzigues, David M. Cash, Jennifer M. Nicholas, Rhian S. Convery, Lucy L. Russell, David L. Thomas, Ian B. Malone, Juan Eugenio Iglesias, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Barbara Borroni, Daniela Galimberti, Raquel Sanchez-Valle, Robert Laforce, Fermin Moreno, Matthis Synofzik, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Rik Vandenberghe, Elizabeth Finger, Fabrizio Tagliavini, Alexandre de Mendonca, Isabel Santana, Chris R. Butler, Simon Ducharme, Alexander Gerhard, Adrian Danek, Johannes Levin, Markus Otto, Sandro Sorbi, Isabelle Le Ber, Florence Pasquier, Jonathan D. Rohrer

Summary: The study quantified brain anomalies on MRI in individuals with C9orf72, MAPT, and GRN mutations. The identified imaging markers associated with clinical and behavioral changes in presymptomatic carriers over one year, providing important data for participant stratification in trials. Biomarkers predicting disease progression in genetic frontotemporal dementia are urgently needed.

BRAIN COMMUNICATIONS (2023)

Editorial Material Neurosciences

The Underestimated Relevance of Alzheimer's Disease Copathology in Amyotrophic Lateral Sclerosis

Lorenzo Barba, Markus Otto, Samir Abu-Rumeileh

Summary: Around 10-15% of amyotrophic lateral sclerosis (ALS) cases show concurrent Alzheimer's disease (AD) pathology. These ALS-AD patients have a higher prevalence of amnestic cognitive disturbances before motor symptoms appear. While cerebrospinal fluid (CSF) AD core biomarkers do not show significant changes in ALS, phosphorylated tau protein levels in blood may increase independently of AD copathology. Neurofilament proteins are consistently elevated in ALS, but there is limited research on their role in ALS-AD. These considerations are important when using fluid biomarkers as inclusion criteria or secondary endpoints in clinical trials.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Clinical Neurology

High diagnostic performance of plasma and cerebrospinal fluid beta-synuclein for sporadic Creutzfeldt-Jakob disease

Samir Abu-Rumeileh, Steffen Halbgebauer, Giuseppe Mario Bentivenga, Lorenzo Barba, Simone Baiardi, Andrea Mastrangelo, Patrick Oeckl, Petra Steinacker, Angela Mammana, Sabina Capellari, Markus Otto, Piero Parchi

Summary: Beta-synuclein is a promising biomarker for synaptic damage in cerebrospinal fluid and blood, and it can accurately distinguish sporadic Creutzfeldt-Jakob disease from non-prion rapidly progressive dementias. It outperforms protein 14-3-3 and total tau in cerebrospinal fluid, and has similar diagnostic value as cerebrospinal fluid biomarkers in plasma. Beta-synuclein may serve as the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Plasma & beta;-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy

Samir Abu-Rumeileh, Lorenzo Barba, Matthias Bache, Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Antje Guettler, Jacqueline Kessler, Joerg Illert, Christian Strauss, Dirk Vordermark, Markus Otto

Summary: The concentrations and prognostic roles of plasma β-synuclein, glial fibrillary acidic protein (GFAP), and neurofilament proteins (NfL and NfH) were analyzed in 33 patients with malignant gliomas. GFAP and NfL levels were higher in glioblastoma patients compared to other tumor cases. Post-surgery, β-syn, NfL, and NfH increased, while GFAP decreased in long-term follow-up. Surgery and/or radiotherapy regimens influenced β-syn and neurofilament concentrations. GFAP and neurofilament levels were significantly associated with survival. Plasma neuronal and astrocytic biomarkers are differentially altered in malignant glioma types and have distinct trajectories after surgical and adjuvant therapy.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

No Data Available